bioMérieux share breaks through €90 and climbs 2% after Deutsche Bank upgrade
The in vitro diagnostics manufacturer extends a rebound underway for several weeks. An upgrade from a major brokerage firm, released this morning, accompanies the movement in a nearly stable Paris market.
A €90 threshold breached, the stock remains far from its resistance level
bioMérieux share gains 1.84% to €91.20 in trading and has broken through its highest level of the last 30 sessions at €89.55, with this level becoming a support. The stock is trading 7.7% above its 20-day moving average and 12.65% above its 200-day moving average, following a gain of 17.37% over one month.
The RSI at 78 reflects an overbought configuration, a signal of technical setup rather than a forecast. The next resistance level is at €93.65. Within the index, the stock ranks in the first half of the SBF 120, which is down 0.02% at the same time, while bioMérieux remains down 19.29% over one year.
Deutsche Bank upgrades to buy and raises price target from €75 to €103
Deutsche Bank upgrades its rating from "hold" to "buy" and raises its price target from €75 to €103, representing an upside potential of approximately 13% compared to today's share price.
The group confirmed on July 28, following its first-half 2026 results, its outlook for 2026: organic revenue growth of between +3% and +5%, CEBIT growth of between 0% and +10%. It also cited among its risks a 17% decline in BIOFIRE respiratory panels.
More recently, the listing of the Biofire test on the WHO emergency list was announced by bioMérieux on October 19. The next milestone is the publication of third-quarter revenue on November 3. To measure the evolution of analyst consensus, this upgrade adds to opinions already published.
